Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
$51.99
$51.95
$14.95
$52.00
$3.71B1.221.68 million shs113 shs
Evolus, Inc. stock logo
EOLS
Evolus
$11.48
-1.9%
$13.55
$7.07
$15.43
$665.15M1.45613,043 shs148,235 shs
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
$9.12
$9.20
$4.30
$13.66
$458.93M1.531.18 million shsN/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
$0.39
$0.19
$28.00
$906K2.19462,687 shs2.25 million shs
ObsEva SA stock logo
OBSV
ObsEva
$0.01
$0.02
$0.08
$2.14
$390K0.688.94 million shs8,190 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
0.00%0.00%0.00%0.00%0.00%
Evolus, Inc. stock logo
EOLS
Evolus
-0.17%-2.90%-15.28%+0.60%+34.33%
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
0.00%0.00%0.00%0.00%0.00%
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
0.00%0.00%0.00%-59.20%-99.25%
ObsEva SA stock logo
OBSV
ObsEva
0.00%+1,150.00%-60.00%-90.00%-94.05%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
N/AN/AN/AN/AN/AN/AN/AN/A
Evolus, Inc. stock logo
EOLS
Evolus
4.2043 of 5 stars
3.53.00.03.53.12.50.6
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/AN/AN/AN/AN/AN/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
N/AN/AN/AN/A
Evolus, Inc. stock logo
EOLS
Evolus
3.00
Buy$20.6079.44% Upside
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
N/AN/AN/AN/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/AN/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/A

Current Analyst Ratings

Latest OBSV, CCXI, EOLS, NEPT, and FLXN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/10/2024
Evolus, Inc. stock logo
EOLS
Evolus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00
3/1/2024
Evolus, Inc. stock logo
EOLS
Evolus
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00
1/29/2024
Evolus, Inc. stock logo
EOLS
Evolus
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$10.00 ➝ $16.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
$32.22M115.14N/AN/A$4.09 per share12.71
Evolus, Inc. stock logo
EOLS
Evolus
$202.09M3.29N/AN/A($0.36) per share-31.89
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
$85.55M5.36N/AN/A($0.34) per share-26.82
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
$52.62M0.00N/AN/A($91.90) per share0.00
ObsEva SA stock logo
OBSV
ObsEva
$20.11M0.02N/AN/A$0.41 per share0.01

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
-$131.76M-$1.89N/AN/AN/A-357.01%-48.52%-30.59%N/A
Evolus, Inc. stock logo
EOLS
Evolus
-$61.69M-$1.09N/AN/AN/A-30.52%N/A-32.19%5/7/2024 (Confirmed)
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
-$113.71M-$2.01N/AN/AN/A-100.32%N/A-44.26%N/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
-$60.46M-$106.72N/AN/AN/A-128.13%N/A-141.94%7/15/2024 (Estimated)
ObsEva SA stock logo
OBSV
ObsEva
-$58.38M-$0.92N/AN/AN/A-416.36%-92.01%N/A

Latest OBSV, CCXI, EOLS, NEPT, and FLXN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Evolus, Inc. stock logo
EOLS
Evolus
-$0.0650N/A+$0.0650N/AN/AN/A
3/7/2024Q4 2023
Evolus, Inc. stock logo
EOLS
Evolus
-$0.15-$0.20-$0.05-$0.19$61.14 million$61.00 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
N/AN/AN/AN/AN/A
Evolus, Inc. stock logo
EOLS
Evolus
N/AN/AN/AN/AN/A
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
N/AN/AN/AN/AN/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/AN/AN/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
0.02
4.54
4.47
Evolus, Inc. stock logo
EOLS
Evolus
N/A
2.33
2.10
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
N/A
4.38
4.05
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/A
0.23
0.10
ObsEva SA stock logo
OBSV
ObsEva
N/A
0.61
0.61

Ownership

Institutional Ownership

CompanyInstitutional Ownership
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
81.09%
Evolus, Inc. stock logo
EOLS
Evolus
90.69%
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
90.01%
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
14.44%
ObsEva SA stock logo
OBSV
ObsEva
17.52%

Insider Ownership

CompanyInsider Ownership
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
8.30%
Evolus, Inc. stock logo
EOLS
Evolus
5.40%
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
9.13%
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
5.10%
ObsEva SA stock logo
OBSV
ObsEva
14.40%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
17871.36 million65.43 millionOptionable
Evolus, Inc. stock logo
EOLS
Evolus
27357.94 million54.82 millionOptionable
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
25750.32 million45.73 millionOptionable
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
584.53 million4.30 millionNot Optionable
ObsEva SA stock logo
OBSV
ObsEva
4877.97 million66.74 millionNot Optionable

OBSV, CCXI, EOLS, NEPT, and FLXN Headlines

SourceHeadline
StockNews.com Initiates Coverage on ObsEva (NASDAQ:OBSV)StockNews.com Initiates Coverage on ObsEva (NASDAQ:OBSV)
americanbankingnews.com - April 20 at 2:22 AM
ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of ListinObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listin
globenewswire.com - April 3 at 1:00 AM
ObsEva Announces Update on Board of DirectorsObsEva Announces Update on Board of Directors
globenewswire.com - March 19 at 2:00 AM
ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023
globenewswire.com - February 28 at 1:00 AM
ObsEva Stock (OTC:OBSEF) Dividends: History, Yield and DatesObsEva Stock (OTC:OBSEF) Dividends: History, Yield and Dates
benzinga.com - February 26 at 12:34 AM
ObsEva SA OBSNObsEva SA OBSN
morningstar.com - November 11 at 10:37 PM
ObsEva SA OBSEFObsEva SA OBSEF
morningstar.com - November 11 at 7:36 AM
ObsEva (NASDAQ: OBSV)ObsEva (NASDAQ: OBSV)
fool.com - June 18 at 11:34 PM
Tocolytic Agents Market to a Steady Revenue CAGR of 5.3% by ... - InvestorsObserverTocolytic Agents Market to a Steady Revenue CAGR of 5.3% by ... - InvestorsObserver
news.google.com - May 10 at 1:37 AM
ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - Yahoo FinanceObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - Yahoo Finance
news.google.com - May 2 at 1:32 PM
ObsEva Says Fabien De Ladonchamps Is New CEO - NasdaqObsEva Says Fabien De Ladonchamps Is New CEO - Nasdaq
news.google.com - May 2 at 8:31 AM
ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - GlobeNewswireObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - GlobeNewswire
news.google.com - May 2 at 1:20 AM
Gameto Appoints Teri Loxam as Chief Financial Officer - citybizGameto Appoints Teri Loxam as Chief Financial Officer - citybiz
news.google.com - April 28 at 11:20 PM
ObsEva Annual Report 2022 - Marketscreener.comObsEva Annual Report 2022 - Marketscreener.com
news.google.com - April 28 at 6:20 PM
ObsEva Annual Report 2022 - Yahoo FinanceObsEva Annual Report 2022 - Yahoo Finance
news.google.com - April 28 at 6:20 PM
ObsEva Annual Report 2022 - BenzingaObsEva Annual Report 2022 - Benzinga
news.google.com - April 28 at 1:20 PM
ObsEva Annual Report 2022 - EIN NewsObsEva Annual Report 2022 - EIN News
news.google.com - April 28 at 1:20 PM
Gameto Expands Executive Team with the Addition of Teri Loxam as ... - PR NewswireGameto Expands Executive Team with the Addition of Teri Loxam as ... - PR Newswire
news.google.com - April 28 at 8:19 AM
Endometriosis Market to Hit USD 3.9 Bn by 2029: Competitive ... - Digital JournalEndometriosis Market to Hit USD 3.9 Bn by 2029: Competitive ... - Digital Journal
news.google.com - April 26 at 6:27 PM
Endometriosis Pain Pipeline Insight, Emerging Therapies, Key Players, and Clinical Stages - openPREndometriosis Pain Pipeline Insight, Emerging Therapies, Key Players, and Clinical Stages - openPR
news.google.com - April 23 at 8:45 PM
ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq - Marketscreener.comObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq - Marketscreener.com
news.google.com - April 21 at 3:44 PM
ObsEva Announces Change of Central Securities Depositary - Yahoo FinanceObsEva Announces Change of Central Securities Depositary - Yahoo Finance
news.google.com - April 20 at 11:41 PM
ObsEva Announces Change of Central Securities Depositary - GlobeNewswireObsEva Announces Change of Central Securities Depositary - GlobeNewswire
news.google.com - April 20 at 1:10 AM
Tackling Reproductive Health and Fertility Care - Pharmaceutical ExecutiveTackling Reproductive Health and Fertility Care - Pharmaceutical Executive
news.google.com - April 13 at 6:41 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

ChemoCentryx logo

ChemoCentryx

NASDAQ:CCXI
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.
Evolus logo

Evolus

NASDAQ:EOLS
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Flexion Therapeutics logo

Flexion Therapeutics

NASDAQ:FLXN
Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.
Neptune Wellness Solutions logo

Neptune Wellness Solutions

NASDAQ:NEPT
Neptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada.
ObsEva logo

ObsEva

NASDAQ:OBSV
ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.